Adverum Biotechnologies to Present at Upcoming Investor Conferences
|Event:||Raymond James 39th Annual Institutional Investors Conference|
|Date:||March 5, 2018|
|Time:||9:15 – 9:45 a.m. ET|
|Event:||Cowen and Company 38th Annual Health Care Conference|
|Date:||March 12, 2018|
|Time:||1:30 – 2:00 p.m. ET|
A live and replay audio webcast of these presentations will be available from Adverum’s website at http://investors.adverum.com.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Chief Financial Officer
Source: Adverum Biotechnologies, Inc.